FLGT Fulgent Genetics Inc

Price (delayed)

$87.07

Market cap

$2.57B

P/E Ratio

4.57

Dividend/share

N/A

EPS

$19.05

Enterprise value

$2.49B

Fulgent Genetics' proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high ...

Highlights
The price to earnings (P/E) is 47% lower than the last 4 quarters average of 8.7
FLGT's gross margin is up by 42% year-on-year
FLGT's quick ratio is up by 37% since the previous quarter but it is down by 18% year-on-year
Fulgent Genetics's debt has increased by 39% from the previous quarter

Key stats

What are the main financial stats of FLGT
Market
Shares outstanding
29.52M
Market cap
$2.57B
Enterprise value
$2.49B
Valuations
Price to earnings (P/E)
4.57
Price to book (P/B)
2.77
Price to sales (P/S)
2.79
EV/EBIT
3.79
EV/EBITDA
3.76
EV/Sales
2.74
Earnings
Revenue
$909.74M
EBIT
$656.65M
EBITDA
$663.32M
Free cash flow
$403.25M
Per share
EPS
$19.05
Free cash flow per share
$13.83
Book value per share
$31.47
Revenue per share
$31.21
TBVPS
$34.99
Balance sheet
Total assets
$1.05B
Total liabilities
$129.13M
Debt
$20.98M
Equity
$912.73M
Working capital
$445.16M
Liquidity
Debt to equity
0.02
Current ratio
4.66
Quick ratio
4.38
Net debt/EBITDA
-0.12
Margins
EBITDA margin
72.9%
Gross margin
79.3%
Net margin
54.2%
Operating margin
72%
Efficiency
Return on assets
65.9%
Return on equity
79.9%
Return on invested capital
123.8%
Return on capital employed
70.7%
Return on sales
72.2%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FLGT stock price

How has the Fulgent Genetics stock price performed over time
Intraday
-0.57%
1 week
-2.92%
1 month
-6.44%
1 year
123.6%
YTD
67.12%
QTD
-5.59%

Financial performance

How have Fulgent Genetics's revenue and profit performed over time
Revenue
$909.74M
Gross profit
$721.77M
Operating income
$655.25M
Net income
$493.45M
Gross margin
79.3%
Net margin
54.2%
FLGT's gross margin is up by 42% year-on-year
The gross profit has grown by 18% from the previous quarter
Fulgent Genetics's revenue has increased by 18% QoQ
The net income has grown by 18% from the previous quarter

Growth

What is Fulgent Genetics's growth rate over time

Valuation

What is Fulgent Genetics stock price valuation
P/E
4.57
P/B
2.77
P/S
2.79
EV/EBIT
3.79
EV/EBITDA
3.76
EV/Sales
2.74
The price to earnings (P/E) is 47% lower than the last 4 quarters average of 8.7
FLGT's EPS is up by 16% since the previous quarter
The price to book (P/B) is 16% lower than the last 4 quarters average of 3.3 and 4.1% lower than the 5-year quarterly average of 2.9
The company's equity rose by 14% QoQ
FLGT's P/S is 48% below its 5-year quarterly average of 5.4 and 30% below its last 4 quarters average of 4.0
Fulgent Genetics's revenue has increased by 18% QoQ

Efficiency

How efficient is Fulgent Genetics business performance
The company's return on invested capital fell by 22% QoQ
The return on equity has declined by 21% since the previous quarter
The company's return on assets fell by 19% QoQ

Dividends

What is FLGT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FLGT.

Financial health

How did Fulgent Genetics financials performed over time
FLGT's current ratio is up by 39% since the previous quarter but it is down by 26% year-on-year
FLGT's quick ratio is up by 37% since the previous quarter but it is down by 18% year-on-year
Fulgent Genetics's debt is 98% less than its equity
Fulgent Genetics's debt has increased by 39% from the previous quarter
FLGT's debt to equity is down by 33% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.